D/2 predictors of favorable outcome in cancer

Immunologic Signatures of Rejection

Volumn , Issue , 2011, Pages 199-210

  Pós, Zoltán ^a   Galon, Jérôme ^b  

^a Center for Human Services   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052828276     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-7219-4_13     Document Type: Chapter

References (49)

1. Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K. & Sethi, G. Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72, 1605-1621 (2006).
2. Atkins, M. et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 11, 3714-3721 (2005).
3. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
4. Ben Baruch, A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol. 16, 38-52 (2006).
5. Brichard, V. G. & Lejeune, D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert. Opin. Biol. Ther. 8, 951-968 (2008).
6. Bui, J. D. & Schreiber, R. D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 19, 203-208 (2007).
7. Camus, M. et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 69, 2685-2693 (2009).
8. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
9. Critchley-Thorne, R. J. et al. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS. Med. 4, e176 (2007).
10. Denardo, D. G., Johansson, M. & Coussens, L. M. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 27, 11-18 (2008).
11. Dhodapkar, M. V., Dhodapkar, K. M. & Palucka, A. K. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death. Differ. 15, 39-50 (2008).
12. Dieu-Nosjean, M. C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26, 4410-4417 (2008).
13. Dong, H. P. et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am. J Clin Pathol. 125, 451-458 (2006).
14. Donskov, F. & Von Der, M. H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24, 1997-2005 (2006).
15. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
16. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004).
17. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527 (2008).
18. Fu, J. et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132, 2328-2339 (2007).
19. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
20. Gao, Q. et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25, 2586-2593 (2007).
21. Grabenbauer, G. G., Lahmer, G., Distel, L. & Niedobitek, G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res. 12, 3355-3360 (2006).
22. Guminski, A. D. & Thompson, J. F. Predicting response to IL-2 therapy for metastatic melanoma. Expert. Rev. Anticancer Ther. 9, 1571-1575 (2009).
23. Ino, K. et al. Inverse correlation between tumoral indoleamine 2, 3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res. 14, 2310-2317 (2008).
24. Jensen, H. K. et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27, 4709-4717 (2009).
25. Kawai, O. et al. Predominant infiltration of macrophages and CD8 (+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113, 1387-1395 (2008).
26. Kirkwood, J. M. & Tarhini, A. A. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J. Clin. Oncol. 27, 2583-2585 (2009).
27. Kirkwood, J. M. et al. Next generation of immunotherapy for melanoma. J Clin Oncol 26, 3445-3455 (2008).
28. Klatte, T. et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol. 179, 61-66 (2008).
29. Krambeck, A. E. et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. U. S. A 103, 10391-10396 (2006).
30. Leffers, N. et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 58, 449-459 (2009).
31. Louahed, J. et al. Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J. Clin. Oncol. (Meeting Abstracts) 26, 9045 (2008).
32. Mager, D. L. Bacteria and cancer: cause, coincidence or cure? A review. J. Transl. Med. 4, 14 (2006).
33. Mlecnik, B. et al. Biomolecular network reconstruction identifies T cell homing factors associated with survival in colorectal cancer. Gastroenterology 138, 1429-1440 (2010).
34. Pages, F. et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2005).
35. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308 (2008).
36. Roth, T. J. et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893-7900 (2007).
37. Sabatino, M. et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol. 27, 2645-2652 (2009).
38. Schon, M. P. & Schon, M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 27, 190-199 (2008).
39. Shen, X. et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 30, 123-129 (2007).
40. Strieter, R. M. et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer 42, 768-778 (2006).
41. Tahara, H. et al. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J. Transl. Med. 7, 45 (2009).
42. Talmadge, J. E., Donkor, M. & Scholar, E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 26, 373-400 (2007).
43. Taylor, R. C., Patel, A., Panageas, K. S., Busam, K. J. & Brady, M. S. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25, 869-875 (2007).
44. Thompson, R. H. et al. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 68, 6054-6058 (2008).
45. Unitt, E. et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J. Hepatol. 45, 246-253 (2006).
46. Vansteenkiste, J. F. et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts) 26, 7501 (2008).
47. Wang, W. et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 13, 1523-1531 (2007).
48. Yurkovetsky, Z. R. et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 13, 2422-2428 (2007).
49. Zhou, J. et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052 (2005).